NCT03139136View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

November 16, 2018

Study Completion Date

August 13, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MBS2320

As described in the arm descriptions

DRUG

Placebo

As described in the arm descriptions

Trial Locations (3)

Unknown

Arensia, Tbilisi

Arensia, Chisinau

Arensia, Bucharest

Sponsors
All Listed Sponsors
lead

Modern Biosciences Ltd

INDUSTRY

NCT03139136 - Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter